Boston Scientific (NYSE:BSX) announced that it completed its acquisition of Preventice Solutions that could be worth up to $1.225 billion. The transaction includes a cash payment of $925 million upfront with up to an additional $300 million in potential commercial milestone payments available. Accounting for the company’s approximately 22% equity stake in Preventice prior to the […]
SERB
Boston Scientific to sell BTG Specialty Pharmaceuticals for $800M
Boston Scientific (NYSE:BSX) announced today that it entered into a definitive agreement to sell its BTG Specialty Pharmaceuticals business. Marlborough, Mass.-based Boston Scientific is selling BTG for $800 million in cash to Stark International Lux S.A.R.L. and SERP SAS, both affiliates of European specialty pharmaceutical group SERB, according to a news release. SERB, which is backed […]
